Real‐world population pharmacokinetics of tezacaftor‐ivacaftor in children with cystic fibrosis: The SYM‐CF study
This is the first study to investigate the popPK of tezacaftor-ivacaftor in cwCF. The established models can be used for more personalized dosing in children experiencing suboptimal efficacy, adverse effects, drug-drug interactions, or where adherence is a concern.
Authors
- Suzanne W. J. Terheggen‐Lagro (ORCID: https://orcid.org/0000-0002-3305-3745)
- Anke H. Maitland‐van der Zee (ORCID: https://orcid.org/0000-0002-0414-3442)
- E. Marleen Kemper (ORCID: https://orcid.org/0000-0003-2275-1713)
- Ron A. A. Mathôt (ORCID: https://orcid.org/0000-0001-8401-0879)
- Hettie M. Janssens (ORCID: https://orcid.org/0000-0002-2210-9176)
- Steffie E. M. Vonk (ORCID: https://orcid.org/0000-0001-9905-7805)
- Eric G. Haarman (ORCID: https://orcid.org/0000-0003-1303-1423)
Institutions
- Erasmus MC (NL)
- Emma Kinderziekenhuis (NL)
- Amsterdam Neuroscience (NL)
- Erasmus MC - Sophia Children’s Hospital (NL)
- Amsterdam University Medical Centers (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-06-13
- DOI
- https://doi.org/10.1002/bcp.70131
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00